Abstract
The great progress of knowledge of both M. tuberculosis physiology and how human host and bacilli interact has provided fertile ground for improving diagnosis and cure of TB infection. Once M. tuberculosis has infected humans, it elaborates strategies for evading the risk to killing by the cells of the host immune system and by the anti-tuberculosis (anti-TB) agents employed to cure infection. These strategies give rise to a bacterial multidrug resistance (MDR) status. This stems firstly from genetic mutations targeting a constellation of drug-processing mechanisms that still need full identification, as drug efflux pumps and drug activating/ inactivating enzymes (genetic resistance). Secondly, from the bacterial adaptation to stressful environmental conditions by adopting a temporary dormancy state lasting for decades and characterized by indifference to anti-TB drugs (phenotypic resistance or tolerance). The clarification of the strategies elaborated for surviving by M. tuberculosis has brought to the identification in the last few years of a number of mycobacterial molecular targets worth to exploitation for the development of novel and powerful anti-TB drugs. These targets include drug-efflux pump systems, considered partly responsible for genetic multi-drug resistance, and several enzymes and pump systems, as well, that sustain the metabolic adaptations of M. tuberculosis in the host and give rise to its phenotypic drug resistance.
Keywords: Genetic/phenotypic resistance, toxin/antitoxin module, DosR regulon, drug efflux pump, bacterial persistence, metabolic adaptations.
Current Medicinal Chemistry
Title:Human Tuberculosis II. M. tuberculosis Mechanisms of Genetic and Phenotypic Resistance to Anti-Tuberculosis Drugs
Volume: 23 Issue: 12
Author(s): Giampietro Sgaragli and Maria Frosini
Affiliation:
Keywords: Genetic/phenotypic resistance, toxin/antitoxin module, DosR regulon, drug efflux pump, bacterial persistence, metabolic adaptations.
Abstract: The great progress of knowledge of both M. tuberculosis physiology and how human host and bacilli interact has provided fertile ground for improving diagnosis and cure of TB infection. Once M. tuberculosis has infected humans, it elaborates strategies for evading the risk to killing by the cells of the host immune system and by the anti-tuberculosis (anti-TB) agents employed to cure infection. These strategies give rise to a bacterial multidrug resistance (MDR) status. This stems firstly from genetic mutations targeting a constellation of drug-processing mechanisms that still need full identification, as drug efflux pumps and drug activating/ inactivating enzymes (genetic resistance). Secondly, from the bacterial adaptation to stressful environmental conditions by adopting a temporary dormancy state lasting for decades and characterized by indifference to anti-TB drugs (phenotypic resistance or tolerance). The clarification of the strategies elaborated for surviving by M. tuberculosis has brought to the identification in the last few years of a number of mycobacterial molecular targets worth to exploitation for the development of novel and powerful anti-TB drugs. These targets include drug-efflux pump systems, considered partly responsible for genetic multi-drug resistance, and several enzymes and pump systems, as well, that sustain the metabolic adaptations of M. tuberculosis in the host and give rise to its phenotypic drug resistance.
Export Options
About this article
Cite this article as:
Sgaragli Giampietro and Frosini Maria, Human Tuberculosis II. M. tuberculosis Mechanisms of Genetic and Phenotypic Resistance to Anti-Tuberculosis Drugs, Current Medicinal Chemistry 2016; 23 (12) . https://dx.doi.org/10.2174/0929867323666160405112820
DOI https://dx.doi.org/10.2174/0929867323666160405112820 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptide Deformylase: A New Target in Antibacterial, Antimalarial and Anticancer Drug Discovery
Current Medicinal Chemistry Adherence to Anti-Retroviral Therapy in North Central Nigeria
Current HIV Research Burkholderia Cepacia Complex Causing Pneumonia in an Immunocompetent Non-Cystic Fibrosis Patient: Case Report and Review of Literature
Infectious Disorders - Drug Targets Preface (Hot Topic: New Frontiers and ”Pitfalls“ in Cytokine and Anti-cytokine Therapies Executive Editor: Atsushi Oda)
Current Pharmaceutical Design Mycobacterium tuberculosis and Dendritic Cells: Whos Manipulating Whom?
Current Immunology Reviews (Discontinued) Armed Imidazo [1,2-a] Pyrimidines (Pyridines): Evaluation of Antibacterial Activity
Letters in Drug Design & Discovery The Application of High Throughput siRNA Screening Technology to Study Host-Pathogen Interactions
Combinatorial Chemistry & High Throughput Screening Isocitrate Lyase: A Potential Target for Anti-Tubercular Drugs
Recent Patents on Inflammation & Allergy Drug Discovery 1,2,4-Oxadiazoles Identified by Virtual Screening and their Non-Covalent Inhibition of the Human 20S Proteasome
Current Medicinal Chemistry An 8-Year Retrospective Study of Human Visceral Leishmaniasis
Current Clinical Pharmacology Development and Implementation of the DHAPP Military eHealth Information Network System
Current HIV Research Current and New Strategies for the Delivery of Antiseptic Agents
Current Drug Delivery Evaluation of Stationary Phases Made by Hydrosilation of Alkynes on Silica Hydride
Current Chromatography Editorial [Hot Topic: New Developments in Drug and Vaccine Discoveries (Executive Editor: Aldar S. Bourinbaiar)]
Current Pharmaceutical Design Lichen Depsidones as Potential Novel Pharmacologically Active Compounds
Mini-Reviews in Organic Chemistry Interplay between Catalysts and Substrates for Activity of Class Ib Aminoacyl-tRNA Synthetases and Implications for Pharmacology
Current Topics in Medicinal Chemistry Structure and Function of RNase AS: A Novel Virulence Factor From Mycobacterium tuberculosis
Current Medicinal Chemistry Macrophage Specific Drug Delivery in Experimental Leishmaniasis
Current Molecular Medicine A Novel Approach to Inhibit Heat Shock Response as Anticancer Strategy by Coumarine Compounds Containing Thiazole Skeleton
Anti-Cancer Agents in Medicinal Chemistry Tuberculosis Therapeutics: Past Achievements, Present Road-Blocks and Future Perspectives
Letters in Drug Design & Discovery